M Truyens, A Cremer, A Jauregui-Amezaga, B Verstockt, J Sabino, L Pouillon, The Bird Group, T Lobatón
{"title":"From theory to practice: a Belgian consensus on minimal monitoring strategies for patients with IBD treated with advanced therapies.","authors":"M Truyens, A Cremer, A Jauregui-Amezaga, B Verstockt, J Sabino, L Pouillon, The Bird Group, T Lobatón","doi":"10.51821/89.2.14879","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and study aims: </strong>Inflammatory bowel diseases (IBD) are chronic conditions requiring lifelong management, often involving advanced therapies. To harmonize the current heterogeneity in monitoring practices we developed a Belgian Standard of Care (SOC) guidance for patients with IBD treated with these advanced therapies.</p><p><strong>Methods: </strong>A multistep approach was adopted. First, a core team of IBD clinicians conducted a national survey to evaluate current practices and identify gaps. Next, a SOC guidance document was drafted and reviewed by multiple stakeholders, including physicians and IBD nurses from the Belgian IBD Research and Development (BIRD) group and patient organizations. Feedback was then incorporated to develop a consensus-based framework tailored to current Belgian clinical practices.</p><p><strong>Results: </strong>This SOC guidance outlines minimal follow-up requirements across treatment phases, emphasizing clinical, biochemical, endoscopic and cross-sectional assessments, while also discussing additional relevant outcomes such as quality of life.</p><p><strong>Conclusions: </strong>The SOC guidance document offers a comprehensive, consensus-based framework to homogenize the monitoring of patients with IBD receiving advanced therapies. By standardizing monitoring practices, it aims to enhance quality of care, safety and long-term outcomes, ensuring alignment with international standards while addressing specific national requirements and availabilities.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"89 2","pages":"315-323"},"PeriodicalIF":1.2000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta gastro-enterologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.51821/89.2.14879","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and study aims: Inflammatory bowel diseases (IBD) are chronic conditions requiring lifelong management, often involving advanced therapies. To harmonize the current heterogeneity in monitoring practices we developed a Belgian Standard of Care (SOC) guidance for patients with IBD treated with these advanced therapies.
Methods: A multistep approach was adopted. First, a core team of IBD clinicians conducted a national survey to evaluate current practices and identify gaps. Next, a SOC guidance document was drafted and reviewed by multiple stakeholders, including physicians and IBD nurses from the Belgian IBD Research and Development (BIRD) group and patient organizations. Feedback was then incorporated to develop a consensus-based framework tailored to current Belgian clinical practices.
Results: This SOC guidance outlines minimal follow-up requirements across treatment phases, emphasizing clinical, biochemical, endoscopic and cross-sectional assessments, while also discussing additional relevant outcomes such as quality of life.
Conclusions: The SOC guidance document offers a comprehensive, consensus-based framework to homogenize the monitoring of patients with IBD receiving advanced therapies. By standardizing monitoring practices, it aims to enhance quality of care, safety and long-term outcomes, ensuring alignment with international standards while addressing specific national requirements and availabilities.
期刊介绍：
The Journal Acta Gastro-Enterologica Belgica principally publishes peer-reviewed original manuscripts, reviews, letters to editors, book reviews and guidelines in the field of clinical Gastroenterology and Hepatology, including digestive oncology, digestive pathology, as well as nutrition. Pure animal or in vitro work will not be considered for publication in the Journal. Translational research papers (including sections of animal or in vitro work) are considered by the Journal if they have a clear relationship to or relevance for clinical hepato-gastroenterology (screening, disease mechanisms and/or new therapies). Case reports and clinical images will be accepted if they represent an important contribution to the description, the pathogenesis or the treatment of a specific gastroenterology or liver problem. The language of the Journal is English. Papers from any country will be considered for publication. Manuscripts submitted to the Journal should not have been published previously (in English or any other language), nor should they be under consideration for publication elsewhere. Unsolicited papers are peer-reviewed before it is decided whether they should be accepted, rejected, or returned for revision. Manuscripts that do not meet the presentation criteria (as indicated below) will be returned to the authors. Papers that go too far beyond the scope of the journal will be also returned to the authors by the editorial board generally within 2 weeks. The Journal reserves the right to edit the language of papers accepted for publication for clarity and correctness, and to make formal changes to ensure compliance with AGEB’s style. Authors have the opportunity to review such changes in the proofs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
